Selected research
Market Analysis & Forecast
Global Live Cell Imaging Software Market Analysis and Forecast 2026-2032
Market perspective
The global Live Cell Imaging Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Live Cell Imaging Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Live Cell Imaging Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Live Cell Imaging Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Live Cell Imaging Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Live Cell Imaging Software include Andor Technology, Fluxion Biosciences, Olympus LS, PerkinElmer, Sartorius, Molecular Devices, Phase Holographic Imaging PHI, Agilent and BioTek, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Live Cell Imaging Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Live Cell Imaging Software, also provides the revenue of main regions and countries. Of the upcoming market potential for Live Cell Imaging Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Cell Imaging Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live Cell Imaging Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Live Cell Imaging Software revenue, projected growth trends, production technology, application and end-user industry.
Live Cell Imaging Software Segment by Company
Andor Technology
Fluxion Biosciences
Olympus LS
PerkinElmer
Sartorius
Molecular Devices
Phase Holographic Imaging PHI
Agilent
BioTek
Nanlive
CytoSMART
AutoLCI
MilliporeSigma
Live Cell Imaging Software Segment by Type
Cloud-based
On Premises
Live Cell Imaging Software Segment by Application
Laboratory
Hospital
Others
Live Cell Imaging Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Cell Imaging Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Cell Imaging Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Cell Imaging Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Live Cell Imaging Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Live Cell Imaging Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Cell Imaging Software revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cloud-based
- On Premises
Applications
- Laboratory
- Hospital
- Others
Companies covered
- Andor Technology
- Fluxion Biosciences
- Olympus LS
- PerkinElmer
- Sartorius
- Molecular Devices
- Phase Holographic Imaging PHI
- Agilent
- BioTek
- Nanlive
- CytoSMART
- AutoLCI
- MilliporeSigma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Live Cell Imaging Software Market by Type
- 1.2.1 Global Live Cell Imaging Software Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Cloud-based
- 1.2.3 On Premises
- 1.3 Live Cell Imaging Software Market by Application
- 1.3.1 Global Live Cell Imaging Software Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Laboratory
- 1.3.3 Hospital
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Live Cell Imaging Software Market Dynamics
- 2.1 Live Cell Imaging Software Industry Trends
- 2.2 Live Cell Imaging Software Industry Drivers
- 2.3 Live Cell Imaging Software Industry Opportunities and Challenges
- 2.4 Live Cell Imaging Software Industry Restraints
3 Global Growth Perspective
- 3.1 Global Live Cell Imaging Software Market Perspective (2021-2032)
- 3.2 Global Live Cell Imaging Software Growth Trends by Region
- 3.2.1 Global Live Cell Imaging Software Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Live Cell Imaging Software Market Size by Region (2021-2026)
- 3.2.3 Global Live Cell Imaging Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Live Cell Imaging Software Revenue by Players
- 4.1.1 Global Live Cell Imaging Software Revenue by Players (2021-2026)
- 4.1.2 Global Live Cell Imaging Software Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Live Cell Imaging Software Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Live Cell Imaging Software Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Live Cell Imaging Software Key Players Headquarters & Area Served
- 4.4 Global Live Cell Imaging Software Players, Product Type & Application
- 4.5 Global Live Cell Imaging Software Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Live Cell Imaging Software Market CR5 and HHI
- 4.6.3 2025 Live Cell Imaging Software Tier 1, Tier 2, and Tier 3
5 Live Cell Imaging Software Market Size by Type
- 5.1 Global Live Cell Imaging Software Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Live Cell Imaging Software Revenue by Type (2021-2032)
- 5.3 Global Live Cell Imaging Software Revenue Market Share by Type (2021-2032)
6 Live Cell Imaging Software Market Size by Application
- 6.1 Global Live Cell Imaging Software Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Live Cell Imaging Software Revenue by Application (2021-2032)
- 6.3 Global Live Cell Imaging Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Andor Technology
- 7.1.1 Andor Technology Company Information
- 7.1.2 Andor Technology Business Overview
- 7.1.3 Andor Technology Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.1.4 Andor Technology Live Cell Imaging Software Product Portfolio
- 7.1.5 Andor Technology Recent Developments
- 7.2 Fluxion Biosciences
- 7.2.1 Fluxion Biosciences Company Information
- 7.2.2 Fluxion Biosciences Business Overview
- 7.2.3 Fluxion Biosciences Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.2.4 Fluxion Biosciences Live Cell Imaging Software Product Portfolio
- 7.2.5 Fluxion Biosciences Recent Developments
- 7.3 Olympus LS
- 7.3.1 Olympus LS Company Information
- 7.3.2 Olympus LS Business Overview
- 7.3.3 Olympus LS Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.3.4 Olympus LS Live Cell Imaging Software Product Portfolio
- 7.3.5 Olympus LS Recent Developments
- 7.4 PerkinElmer
- 7.4.1 PerkinElmer Company Information
- 7.4.2 PerkinElmer Business Overview
- 7.4.3 PerkinElmer Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.4.4 PerkinElmer Live Cell Imaging Software Product Portfolio
- 7.4.5 PerkinElmer Recent Developments
- 7.5 Sartorius
- 7.5.1 Sartorius Company Information
- 7.5.2 Sartorius Business Overview
- 7.5.3 Sartorius Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.5.4 Sartorius Live Cell Imaging Software Product Portfolio
- 7.5.5 Sartorius Recent Developments
- 7.6 Molecular Devices
- 7.6.1 Molecular Devices Company Information
- 7.6.2 Molecular Devices Business Overview
- 7.6.3 Molecular Devices Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.6.4 Molecular Devices Live Cell Imaging Software Product Portfolio
- 7.6.5 Molecular Devices Recent Developments
- 7.7 Phase Holographic Imaging PHI
- 7.7.1 Phase Holographic Imaging PHI Company Information
- 7.7.2 Phase Holographic Imaging PHI Business Overview
- 7.7.3 Phase Holographic Imaging PHI Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.7.4 Phase Holographic Imaging PHI Live Cell Imaging Software Product Portfolio
- 7.7.5 Phase Holographic Imaging PHI Recent Developments
- 7.8 Agilent
- 7.8.1 Agilent Company Information
- 7.8.2 Agilent Business Overview
- 7.8.3 Agilent Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.8.4 Agilent Live Cell Imaging Software Product Portfolio
- 7.8.5 Agilent Recent Developments
- 7.9 BioTek
- 7.9.1 BioTek Company Information
- 7.9.2 BioTek Business Overview
- 7.9.3 BioTek Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.9.4 BioTek Live Cell Imaging Software Product Portfolio
- 7.9.5 BioTek Recent Developments
- 7.10 Nanlive
- 7.10.1 Nanlive Company Information
- 7.10.2 Nanlive Business Overview
- 7.10.3 Nanlive Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.10.4 Nanlive Live Cell Imaging Software Product Portfolio
- 7.10.5 Nanlive Recent Developments
- 7.11 CytoSMART
- 7.11.1 CytoSMART Company Information
- 7.11.2 CytoSMART Business Overview
- 7.11.3 CytoSMART Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.11.4 CytoSMART Live Cell Imaging Software Product Portfolio
- 7.11.5 CytoSMART Recent Developments
- 7.12 AutoLCI
- 7.12.1 AutoLCI Company Information
- 7.12.2 AutoLCI Business Overview
- 7.12.3 AutoLCI Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.12.4 AutoLCI Live Cell Imaging Software Product Portfolio
- 7.12.5 AutoLCI Recent Developments
- 7.13 MilliporeSigma
- 7.13.1 MilliporeSigma Company Information
- 7.13.2 MilliporeSigma Business Overview
- 7.13.3 MilliporeSigma Live Cell Imaging Software Revenue and Gross Margin (2021-2026)
- 7.13.4 MilliporeSigma Live Cell Imaging Software Product Portfolio
- 7.13.5 MilliporeSigma Recent Developments
8 North America
- 8.1 North America Live Cell Imaging Software Revenue (2021-2032)
- 8.2 North America Live Cell Imaging Software Revenue by Type (2021-2032)
- 8.2.1 North America Live Cell Imaging Software Revenue by Type (2021-2026)
- 8.2.2 North America Live Cell Imaging Software Revenue by Type (2027-2032)
- 8.3 North America Live Cell Imaging Software Revenue Share by Type (2021-2032)
- 8.4 North America Live Cell Imaging Software Revenue by Application (2021-2032)
- 8.4.1 North America Live Cell Imaging Software Revenue by Application (2021-2026)
- 8.4.2 North America Live Cell Imaging Software Revenue by Application (2027-2032)
- 8.5 North America Live Cell Imaging Software Revenue Share by Application (2021-2032)
- 8.6 North America Live Cell Imaging Software Revenue by Country
- 8.6.1 North America Live Cell Imaging Software Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Live Cell Imaging Software Revenue by Country (2021-2026)
- 8.6.3 North America Live Cell Imaging Software Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Live Cell Imaging Software Revenue (2021-2032)
- 9.2 Europe Live Cell Imaging Software Revenue by Type (2021-2032)
- 9.2.1 Europe Live Cell Imaging Software Revenue by Type (2021-2026)
- 9.2.2 Europe Live Cell Imaging Software Revenue by Type (2027-2032)
- 9.3 Europe Live Cell Imaging Software Revenue Share by Type (2021-2032)
- 9.4 Europe Live Cell Imaging Software Revenue by Application (2021-2032)
- 9.4.1 Europe Live Cell Imaging Software Revenue by Application (2021-2026)
- 9.4.2 Europe Live Cell Imaging Software Revenue by Application (2027-2032)
- 9.5 Europe Live Cell Imaging Software Revenue Share by Application (2021-2032)
- 9.6 Europe Live Cell Imaging Software Revenue by Country
- 9.6.1 Europe Live Cell Imaging Software Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Live Cell Imaging Software Revenue by Country (2021-2026)
- 9.6.3 Europe Live Cell Imaging Software Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Live Cell Imaging Software Revenue (2021-2032)
- 10.2 China Live Cell Imaging Software Revenue by Type (2021-2032)
- 10.2.1 China Live Cell Imaging Software Revenue by Type (2021-2026)
- 10.2.2 China Live Cell Imaging Software Revenue by Type (2027-2032)
- 10.3 China Live Cell Imaging Software Revenue Share by Type (2021-2032)
- 10.4 China Live Cell Imaging Software Revenue by Application (2021-2032)
- 10.4.1 China Live Cell Imaging Software Revenue by Application (2021-2026)
- 10.4.2 China Live Cell Imaging Software Revenue by Application (2027-2032)
- 10.5 China Live Cell Imaging Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Live Cell Imaging Software Revenue (2021-2032)
- 11.2 Asia Live Cell Imaging Software Revenue by Type (2021-2032)
- 11.2.1 Asia Live Cell Imaging Software Revenue by Type (2021-2026)
- 11.2.2 Asia Live Cell Imaging Software Revenue by Type (2027-2032)
- 11.3 Asia Live Cell Imaging Software Revenue Share by Type (2021-2032)
- 11.4 Asia Live Cell Imaging Software Revenue by Application (2021-2032)
- 11.4.1 Asia Live Cell Imaging Software Revenue by Application (2021-2026)
- 11.4.2 Asia Live Cell Imaging Software Revenue by Application (2027-2032)
- 11.5 Asia Live Cell Imaging Software Revenue Share by Application (2021-2032)
- 11.6 Asia Live Cell Imaging Software Revenue by Country
- 11.6.1 Asia Live Cell Imaging Software Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Live Cell Imaging Software Revenue by Country (2021-2026)
- 11.6.3 Asia Live Cell Imaging Software Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Live Cell Imaging Software Revenue (2021-2032)
- 12.2 SAMEA Live Cell Imaging Software Revenue by Type (2021-2032)
- 12.2.1 SAMEA Live Cell Imaging Software Revenue by Type (2021-2026)
- 12.2.2 SAMEA Live Cell Imaging Software Revenue by Type (2027-2032)
- 12.3 SAMEA Live Cell Imaging Software Revenue Share by Type (2021-2032)
- 12.4 SAMEA Live Cell Imaging Software Revenue by Application (2021-2032)
- 12.4.1 SAMEA Live Cell Imaging Software Revenue by Application (2021-2026)
- 12.4.2 SAMEA Live Cell Imaging Software Revenue by Application (2027-2032)
- 12.5 SAMEA Live Cell Imaging Software Revenue Share by Application (2021-2032)
- 12.6 SAMEA Live Cell Imaging Software Revenue by Country
- 12.6.1 SAMEA Live Cell Imaging Software Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Live Cell Imaging Software Revenue by Country (2021-2026)
- 12.6.3 SAMEA Live Cell Imaging Software Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst